IP Library › Patent Application 16284456
Patent Application
App. No. 16/284,456

Method for Treating Obesity

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/284,456
Abstract

The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Claims (22)

1 . A method of treating obesity in a mammal comprising administering to a mammal in need of such treatment a composition according to claim 13 .

2 . The method according to claim 1 , wherein said anticonvulsant is of the formula (I):

wherein X is CH 2 or oxygen,

R 1 is hydrogen or alkyl,

R 2 , R 3 , R 4 and R 5 are independently hydrogen or lower alkyl, and when X is CH 2 , R 4 and R 5 can be alkene groups joined to form a benzene ring and when X is oxygen, R 2 and R 3 and/or R 4 and R 5 together can be a methylenedioxy group of the following formula (II):

wherein

R 6 and R 7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.

3 . The method according to claim 2 wherein R 1 is hydrogen or a C 1 -C 4 alkyl, straight and branched chain, and R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are a C 1 -C 3 alkyl, straight or branched chain.

4 . (canceled)

5 . The method according to claim 1 wherein said anticonvulsant is zonisamide or topiramate.

6 . (canceled)

7 . (canceled)

8 . (canceled)

9 . (canceled)

10 . A method of reducing the risk of hypertension, diabetes or dyslipidaemia in a mammal comprising administering to a mammal in need of such reduction a composition according to claim 13 .

11 . (canceled)

12 . (canceled)

13 . A composition comprising at least one weight loss-promoting anticonvulsant and at least one compound that enhances the activity of norepinephrine and/or dopamine selected from the group consisting of bupropion, atomoxetine, and reboxetine.

14 . The composition according to claim 13 wherein said compound is in dosage unit form.

15 . The composition according to claim 14 wherein said composition is in the form of a tablet or capsule.

16 . The composition according to claim 13 wherein said anticonvulsant is zonisamide or topiramate.

17 . The composition according to claim 13 wherein said compound that enhances the activity of norepinephrine and/or dopamine is bupropion.